BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19037840)

  • 1. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.
    Minkovsky N; Berezov A
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1336-46. PubMed ID: 19037840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
    Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
    J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib (BIBW 2992) development in non-small-cell lung cancer.
    Hirsh V
    Future Oncol; 2011 Jul; 7(7):817-25. PubMed ID: 21732753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
    Yap TA; Vidal L; Adam J; Stephens P; Spicer J; Shaw H; Ang J; Temple G; Bell S; Shahidi M; Uttenreuther-Fischer M; Stopfer P; Futreal A; Calvert H; de Bono JS; Plummer R
    J Clin Oncol; 2010 Sep; 28(25):3965-72. PubMed ID: 20679611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib for the treatment of metastatic non-small cell lung cancer.
    Joshi M; Rizvi SM; Belani CP
    Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
    Lin NU; Winer EP; Wheatley D; Carey LA; Houston S; Mendelson D; Munster P; Frakes L; Kelly S; Garcia AA; Cleator S; Uttenreuther-Fischer M; Jones H; Wind S; Vinisko R; Hickish T
    Breast Cancer Res Treat; 2012 Jun; 133(3):1057-65. PubMed ID: 22418700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
    De Grève J; Teugels E; Geers C; Decoster L; Galdermans D; De Mey J; Everaert H; Umelo I; In't Veld P; Schallier D
    Lung Cancer; 2012 Apr; 76(1):123-7. PubMed ID: 22325357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches.
    Fuchs N; Zhang L; Calvo-Barreiro L; Kuncewicz K; Gabr M
    J Pers Med; 2024 Jan; 14(1):. PubMed ID: 38248769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity.
    Marret G; Temam S; Kamal M; Even C; Delord JP; Hoffmann C; Dolivet G; Malard O; Fayette J; Capitain O; Vergez S; Geoffrois L; Rolland F; Zrounba P; Laccourreye L; Saada-Bouzid E; Aide N; Bénavent V; Klijianenko J; Lamy C; Girard E; Vacher S; Masliah-Planchon J; de Koning L; Puard V; Borcoman E; Jimenez M; Bièche I; Gal J; Le Tourneau C
    Sci Rep; 2023 Dec; 13(1):22524. PubMed ID: 38110561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.
    Chang Y; Funk M; Roy S; Stephenson E; Choi S; Kojouharov HV; Chen B; Pan Z
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future perspectives in HER2 positive advanced gastric cancer.
    Roviello G; Catalano M; Iannone LF; Marano L; Brugia M; Rossi G; Aprile G; Antonuzzo L
    Clin Transl Oncol; 2022 Jun; 24(6):981-996. PubMed ID: 35091998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target.
    Zalcman N; Gutreiman M; Shahar T; Weller M; Lavon I
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring effects of DNA methylation and gene expression on pan-cancer drug response by mathematical models.
    Lv W; Zhang X; Dong H; Wu Q; Sun B; Zhang Y
    Exp Biol Med (Maywood); 2021 Jul; 246(14):1626-1642. PubMed ID: 33910405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.
    You KS; Yi YW; Cho J; Seong YS
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
    Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
    Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer.
    Yang X; Wu D; Yuan S
    Technol Cancer Res Treat; 2020; 19():1533033820962140. PubMed ID: 33034269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer.
    Piesche M; Roos J; Kühn B; Fettel J; Hellmuth N; Brat C; Maucher IV; Awad O; Matrone C; Comerma Steffensen SG; Manolikakes G; Heinicke U; Zacharowski KD; Steinhilber D; Maier TJ
    Front Pharmacol; 2020; 11():1297. PubMed ID: 33013366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ATF6-EGF Pathway Mediates the Awakening of Slow-Cycling Chemoresistant Cells and Tumor Recurrence by Stimulating Tumor Angiogenesis.
    Cho J; Min HY; Pei H; Wei X; Sim JY; Park SH; Hwang SJ; Lee HJ; Hong S; Shin YK; Lee HY
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
    Lin X; Liao J; Geng X; Dan H; Chen L
    Am J Transl Res; 2020; 12(3):847-856. PubMed ID: 32269717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.